Cargando…

Human Hyaluronidase PH20 Potentiates the Antitumor Activities of Mesothelin-Specific CAR-T Cells Against Gastric Cancer

T cell infiltration into tumors is essential for successful immunotherapy against solid tumors. Herein, we found that the expression of hyaluronic acid synthases (HAS) was negatively correlated with patient survival in multiple types of solid tumors including gastric cancer. HA impeded in vitro anti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Ruocong, Cui, Yuanbin, Zheng, Yongfang, Li, Shanglin, Lv, Jiang, Wu, Qiting, Long, Youguo, Wang, Suna, Yao, Yao, Wei, Wei, Yang, Jie, Wang, Bin-Chao, Zhang, Zhenfeng, Zeng, Hui, Li, Yangqiu, Li, Peng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8313856/ https://www.ncbi.nlm.nih.gov/pubmed/34326835 http://dx.doi.org/10.3389/fimmu.2021.660488

Ejemplares similares

DAP10 integration in CAR-T cells enhances the killing of heterogeneous tumors by harnessing endogenous NKG2D
por: Li, Shanglin, et al.
Publicado: (2022)

Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer
por: Lv, Jiang, et al.
Publicado: (2019)

Co-expression of a PD-L1-specific chimeric switch receptor augments the efficacy and persistence of CAR T cells via the CD70-CD27 axis
por: Qin, Le, et al.
Publicado: (2022)

Current status and hurdles for CAR-T cell immune therapy
por: Zhao, Ruocong, et al.
Publicado: (2019)

The antitumor capacity of mesothelin-CAR-T cells in targeting solid tumors in mice
por: Zhang, Qian, et al.
Publicado: (2021)

Chimeric CTLA4-CD28-CD3z T Cells Potentiate Antitumor Activity Against CD80/CD86–Positive B Cell Malignancies
por: Lin, Shouheng, et al.
Publicado: (2021)

Incorporation of functional elements enhances the antitumor capacity of CAR T cells
por: Qin, Le, et al.
Publicado: (2017)

DNAX-activating protein 10 co-stimulation enhances the anti-tumor efficacy of chimeric antigen receptor T cells
por: Zhao, Ruocong, et al.
Publicado: (2018)

Chimeric antigen receptor T cells targeting PD-L1 suppress tumor growth
por: Qin, Le, et al.
Publicado: (2020)

PSCA is a target of chimeric antigen receptor T cells in gastric cancer
por: Wu, Di, et al.
Publicado: (2020)

The Chemokine Receptor CCR8 Is a Target of Chimeric Antigen T Cells for Treating T Cell Malignancies
por: Zheng, Diwei, et al.
Publicado: (2022)

Modified CAR T cells targeting membrane-proximal epitope of mesothelin enhances the antitumor function against large solid tumor
por: Zhang, Zhiwei, et al.
Publicado: (2019)

Highly active CAR T cells that bind to a juxtamembrane region of mesothelin and are not blocked by shed mesothelin
por: Liu, Xiufen, et al.
Publicado: (2022)

Active Expression of Human Hyaluronidase PH20 and Characterization of Its Hydrolysis Pattern
por: Pang, Bo, et al.
Publicado: (2022)

Correction: Modified CAR T cells targeting membrane-proximal epitope of mesothelin enhances the antitumor function against large solid tumor
por: Zhang, Zhiwei, et al.
Publicado: (2020)

Disruption of CISH promotes the antitumor activity of human T cells and decreases PD-1 expression levels
por: Lv, Jiang, et al.
Publicado: (2022)

Challenges of Anti-Mesothelin CAR-T-Cell Therapy
por: Zhai, Xuejia, et al.
Publicado: (2023)

Mesothelin-targeted second generation CAR-T cells inhibit growth of mesothelin-expressing tumors in vivo
por: Ye, Lin, et al.
Publicado: (2019)

Anti-Mesothelin CAR T cell therapy for malignant mesothelioma
por: Castelletti, Laura, et al.
Publicado: (2021)

Mesothelin-targeted CAR-T cells for adoptive cell therapy of solid tumors
por: Zhang, Gui-Zhen, et al.
Publicado: (2019)

IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin
por: Pang, Nengzhi, et al.
Publicado: (2021)

Chondrocytes, synoviocytes and dermal fibroblasts all express PH-20, a hyaluronidase active at neutral pH
por: El Hajjaji, Hafida, et al.
Publicado: (2005)

Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells
por: Qin, Le, et al.
Publicado: (2017)

Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration
por: Rosengren, Sanna, et al.
Publicado: (2015)

Development of mesothelin-specific CAR NK-92 cells for the treatment of gastric cancer
por: Cao, Bihui, et al.
Publicado: (2021)

Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors
por: Wang, Zhenguang, et al.
Publicado: (2021)

Efficient growth suppression in pancreatic cancer PDX model by fully human anti-mesothelin CAR-T cells
por: Jiang, Hua, et al.
Publicado: (2017)

Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours
por: Infante, Jeffrey R, et al.
Publicado: (2018)

Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours
por: Infante, Jeffrey R, et al.
Publicado: (2018)

Hyaluronidase and pH Dual-Responsive Nanoparticles for Targeted Breast Cancer Stem Cells
por: Li, Weinan, et al.
Publicado: (2021)

Bioorthogonal Equipping CAR-T Cells with Hyaluronidase and Checkpoint Blocking Antibody for Enhanced Solid Tumor Immunotherapy
por: Zhao, Yangyang, et al.
Publicado: (2022)

Human induced-T-to-natural killer cells have potent anti-tumour activities
por: Jiang, Zhiwu, et al.
Publicado: (2022)

ENHANZE(®) drug delivery technology: a novel approach to subcutaneous administration using recombinant human hyaluronidase PH20
por: Locke, Kenneth W., et al.
Publicado: (2019)

A Preclinical Investigation into the Effects of Aging on Dermal Hyaluronan Properties and Reconstitution Following Recombinant Human Hyaluronidase PH20 Administration
por: Connor, Robert J., et al.
Publicado: (2020)

Dispersive effects and focused biodistribution of recombinant human hyaluronidase PH20: A locally acting and transiently active permeation enhancer
por: Kang, David W., et al.
Publicado: (2021)

Mesothelin-Specific Immune Responses and Targeted Immunotherapy for Mesothelin-Expressing Tumors
por: Einama, Takahiro, et al.
Publicado: (2017)

Mesothelin as a biomarker for targeted therapy
por: Lv, Jiang, et al.
Publicado: (2019)

Anti-GPC3-CAR T Cells Suppress the Growth of Tumor Cells in Patient-Derived Xenografts of Hepatocellular Carcinoma
por: Jiang, Zhiwu, et al.
Publicado: (2017)

Genetic and pharmacological targeting of A2a receptor improves function of anti-mesothelin CAR T cells
por: Masoumi, Elham, et al.
Publicado: (2020)

A hyaluronidase activity of the sperm plasma membrane protein PH-20 enables sperm to penetrate the cumulus cell layer surrounding the egg
Publicado: (1994)

Cannot write session to /tmp/vufind_sessions/sess_k9ph4okeajeiq01p5r45uttg52